Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Puzanov, Igor, Agarwala, Sanjiv S., Blank, Christian, Carvajal, Richard D., Demaria, Sandra, Dummer, Reinhard, Ernstoff, Marc, Ferrone, Soldano, Fox, Bernard A., Gajewski, Thomas F., Garbe, Claus, Hwu, Patrick, Lo, Roger S., Long, Georgina V., Luke, Jason J., Osman, Iman, Postow, Michael A., Sullivan, Ryan J., Taube, Janis M., Trinchieri, Giorgio, Zarour, Hassane M., Caracò, Corrado, Thurin, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487701/
https://www.ncbi.nlm.nih.gov/pubmed/32894202
http://dx.doi.org/10.1186/s12967-020-02482-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487701/
https://www.ncbi.nlm.nih.gov/pubmed/32894202
http://dx.doi.org/10.1186/s12967-020-02482-x

Ejemplares similares